Chul Kim: What are other relevant targets for ADC therapy in NSCLC?

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:

“What are other relevant targets for Antibody Drug Conjugates (ADCs) therapy in Non-small cell lung cancer (NSCLC)? Farletuzumab ecteribulin (FRalpha), patritumab deruxtecan (HER3), SGN-B6A (integrin beta-6) are being actively investigated. Awesome talk by Maria Antonia Vélez (hematology/oncology fellow at UCLA)!”

Image

Source: Chul Kim/X

Antibody Drug Conjugates (ADCs) cancer Chul Kim Farletuzumab ecteribulin Georgetown University Maria Antonia Vélez non small cell lung cancer NSCLC OncoDaily Oncology patritumab deruxtecan SGN-B6A Thoracic Medical Oncologist UCLA